Travere Therapeutics, Inc. (TVTX) Earnings Call Transcripts
Travere Therapeutics, Inc.'s Latest Earnings Call - June 2, 2026
In the second quarter of fiscal year 2026, Travere Therapeutics announced a significant exclusive licensing and collaboration agreement with Everest Medicines for seborbrutinib, a potential best-in-class reversible BTK inhibitor. This strategic transaction is expected to enhance Travere's rare kidney disease portfolio and provide long-term growth potential. While specific revenue and earnings figures were not disclosed, management expressed confidence in the future performance of seborbrutinib, particularly in addressing unmet needs in primary membranous nephropathy and other immune-mediated kidney diseases.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | |
| Earnings | |
| Anti-PLA2R Antibody Reduction (Cohort 1) | 62% (positive) |
| Anti-PLA2R Antibody Reduction (Cohort 2) | 87% (positive) |
| Proteinuria Reduction (Cohort 1) | 77% (positive) |
| Proteinuria Reduction (Cohort 2) | 80% (positive) |
Guidance from management
Management signaled a strong commitment to advancing seborbrutinib through clinical development, with plans to align with global regulators post-transaction. They expressed confidence in the asset's potential to drive long-term growth.
What management said
Yes. We do see continued durability of off treatment, but it is still very early to be able to discuss that and we haven't made final decisions around dosing or duration -- once the deal closes, we'll be able to give more details around our strategy and planning for that. Because I think what you're getting at is this a long-term treatment? Is this induction treatment. The fact that there is some durability off targe...
Yes. So the only other BTK inhibitor that has early data provides proof of concept that the mechanism likely works However, that's -- and I think you mentioned it's an ibrutinib. However, that is a slightly different mechanism. That is an irreversible covalent BTK inhibitor. And therefore, we do believe that the fact that we are covalent reversible has a potential for a better safety profile overall with regards to w...
What analysts pressed on
Analysts raised questions regarding the safety profile of seborbrutinib compared to other BTK inhibitors and the potential for liver toxicity. There were also inquiries about the specifics of the development path and regulatory strategy moving forward.
Main topics on the call
- Exclusive Licensing Agreement — Travere entered into an exclusive licensing agreement with Everest Medicines for seborbrutinib, which will provide development and commercialization rights outside of China. Dr. Eric Dube stated, "This is an exciting and...
- Clinical Evidence for Seborbrutinib — The ongoing Phase Ib/IIa study of seborbrutinib shows promising results, with anti-PLA2R antibody levels declining by approximately 62% and 87% in two cohorts. Dr. Jula Inrig emphasized that these results provide "import...
- Market Positioning — Seborbrutinib is positioned as a potential best-in-class product with a differentiated oral formulation that could offer convenience and a favorable safety profile. Dr. Dube noted, "Civoribrutinib will bring pipeline and...
- Regulatory Strategy — Management indicated that they plan to work closely with global regulators to align on the next stages of clinical development for seborbrutinib. Dr. Dube mentioned, "Our intent is to make sure that we can move very quic...
Read the full Travere Therapeutics, Inc. transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 68 calls on record spanning February 24, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 68 Travere Therapeutics, Inc. earnings call transcripts on record, spanning February 24, 2020 to August 4, 2026. Based on this history, Travere Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- TVTX
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 68
- First call
- February 24, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly